|
|
Caspian Journal of Internal Medicine، جلد ۱۳، شماره ۱، صفحات ۶۱-۶۹
|
|
|
| عنوان فارسی |
|
|
| چکیده فارسی مقاله |
|
|
| کلیدواژه‌های فارسی مقاله |
|
|
| عنوان انگلیسی |
Two trade names of deferasirox (Osveral® and Exjade®) in reduction of iron overload parameters in major beta-thalassemia patients: A randomized open labeled clinical trial |
|
| چکیده انگلیسی مقاله |
Background: Beta-thalassemia major patients typically require chronic transfusion and iron-chelating agents to reduce serum iron overload. Osveral® is an available Iranian brand name of deferasirox used by majority of thalassemic patients. The aim of this study was to compare the efficacy of Osveral® vs. Exjade® in major beta- thalassemia patients. Methods: In this randomized clinical trial, all patients received a single daily dose of 30 mg/kg either of Osveral® or Exjade® for 6 months. Primary outcome was the mean of bimonthly changes in serum ferritin concentration and secondary outcomes included mean changes of heart and liver MRI T2* after a year. Results: Finally, 80 patients completed the study. The mean serum ferritin level at the end of sixth month significantly decreased in Osveral® and Exjade® groups (p< 0.01). After a year, means cardiac MRI T2* in Osveral® group were changed from 25.9±9.6 ms to 25.4±9.7 ms and in Exjade® group from 24.8±9.2 ms to 26.9±5.9 ms, with no significant difference (P=0.43). Mean liver MRI T2* for Osveral® and Exjade® groups were 8.6±6.4 ms (baseline 6.3±4.7) and 6.3±4 ms (baseline 4.9±3.5), respectively and there was no significant difference between two study arms (P=0.1). Conclusion: Osveral® decreased significantly the serum ferritin level and improved heart and liver iron overload as efficient as Exjade®. It can be a suitable cost-effective alternative agent in beta-thalassemia major patients. |
|
| کلیدواژه‌های انگلیسی مقاله |
Deferasirox, Osveral, Exjade, Ferritin, MRI T2* |
|
| نویسندگان مقاله |
| Mohammadreza Rafati
Pharmaceutical Research Center, Department of Clinical Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran.
| Hossein Karami
Department of Pediatrics, College of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
| Bita Lashtoo-Aghaee
Emam Sajjad Hospital, Ramsar, Iran
| Bahareh Lashtoo-Aghaee
Department of Microbiology, College of Medicine, Tehran University of Medical Sciences, Tehran, Iran
| Mojdeh Dabirian
Department of cardiology, College of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
| Razieh Avan
Department of Clinical Pharmacy, Medical Toxicology and Drug Abuse Research Center (MTDRC), Faculty of Pharmacy, Birjand University of Medical Sciences, Birjand, Iran
|
|
| نشانی اینترنتی |
http://caspjim.com/browse.php?a_code=A-10-1976-1&slc_lang=en&sid=1 |
| فایل مقاله |
فایلی برای مقاله ذخیره نشده است |
| کد مقاله (doi) |
|
| زبان مقاله منتشر شده |
en |
| موضوعات مقاله منتشر شده |
pharmacology |
| نوع مقاله منتشر شده |
Original Article |
|
|
|
برگشت به:
صفحه اول پایگاه |
نسخه مرتبط |
نشریه مرتبط |
فهرست نشریات
|